Mycobacterium tuberculosis MicroEvolution Database

In its only known natural environment, the human host, Mycobacterium tuberculosis faces two principle selective pressures: host immunity and anti-TB drugs. Each of these forces may influence the course of disease and treatment. Understanding the interaction of M. tuberculosis with the host immune system is necessary for vaccine development, and knowledge of drug resistance mutations and mechanisms is essential for both clinical diagnostic tools and development of new and more effective anti-TB drugs. This project seeks to address the effects of immune and anti-TB drug pressures, both in isolation and acting in concert, and thus provide the first comprehensive view of the selective forces acting on this medically important organism. This knowledge will contribute directly to discovery of urgently needed new drug targets, diagnostics and vaccines for tuberculosis. The first goal of this project is to study the selective pressure of anti-TB drugs acting alone on TB. The second goal of this project is to understand the selective pressure of the host immune system on TB. Samples are in the queue for sequencing, check back for data.

This sequencing project was supported by the National Institute of Allergy and Infectious Disease, National Institutes of Health funded Genome Sequencing Center for Infectious Diseases at the Broad Institute.